CagriSema is a subcutaneous injectable combination of cagrilintide and semaglutide that is currently in phase 3 trials.
Vidhi Patel, PharmD Candidate
Advertisement
Articles by Vidhi Patel, PharmD Candidate
Metformin may accelerate paclitaxel’s actions on cell replication in endometrial cancer.
Thiazolidinediones may change metabolic patterns and contribute to weight gain.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Beyond Injections: The Rise of Oral GLP-1 Therapy
3
FAQs Amid the Ongoing US Measles Outbreaks
4
Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia
5